IL6 and Insulin resistance: Then, compared to the placebo, significant increases in high-density lipoprotein (HDL) and quantitative insulin sensitivity check index (QUICKI) and significant decreases in fatty liver degree, liver transaminases, waist circumference, fasting blood sugar and insulin (FBS and FBI), triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL), homeostasis model assessment insulin resistance (HOMA-IR), tumor necrosis factor-α (TNF-α), high sensitive c-reactive protein (hs-CRF), and interleukin-6 (IL-6) were reported in these clinical trials.